Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression.

Trial Profile

Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2017 According to an Immune Therapeutics media release, the company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines. The application will include results of four phase II clinical trials and one bridging trial clinical trial.
    • 26 Oct 2016 According to Immune Therapeutics media release, the Ministry of Health and Prevention Division of Pharmacy in the Republic of Senegal (the "Ministry of Health") accepted for review the Company's New Drug Applications ("NDAs") for LodonalTM as a stand alone or adjunct therapy non-toxic in the treatment of HIV/AIDS, cancer and as an immune booster.
    • 18 Aug 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top